This treatment is deemed plausible on the basis of an increase in U2OS and DT40 cell sensitivity to PARP inhibitors after BAP1 depletion44,46 and on the 769-P ccRCC cell line carrying an inactivating BAP1 mutation that makes it more sensitive to IR and the PARP inhibitor olaparib than control cells carrying wild-type BAP19. This evidence concerns the gene BAP1 and nonpapillary renal cell carcinoma.